Abstract:Significance Identifying biological targets in major depressive disorder (MDD) is a critical step for development of effective mechanism-based medications. The epigenetic agent acetyl-l-carnitine (LAC) has rapid and enduring antidepressant-like effects in LAC-deficient rodents. Here, we found that LAC levels were decreased in patients with MDD versus age- and sex-matched healthy controls in two independent study centers. In subsequent exploratory analyses, the degree of LAC deficiency reflected both the severity and age of onset of MDD. Furthermore, the lowest LAC levels were found in patients with treatment-resistant depression, whereby history of emotional neglect and being female predicted decreased LAC levels. These translational findings suggest that LAC may serve as a candidate biomarker to help the diagnosis of a clinical endophenotype of MDD. The lack of biomarkers to identify target populations greatly limits the promise of precision medicine for major depressive disorder (MDD), a primary cause of ill health and disability. The endogenously produced molecule acetyl-l-carnitine (LAC) is critical for hippocampal function and several behavioral domains. In rodents with depressive-like traits, LAC levels are markedly decreased and signal abnormal hippocampal glutamatergic function and dendritic plasticity. LAC supplementation induces rapid and lasting antidepressant-like effects via epigenetic mechanisms of histone acetylation. This mechanistic model led us to evaluate LAC levels in humans. We found that LAC levels, and not those of free carnitine, were decreased in patients with MDD compared with age- and sex-matched healthy controls in two independent study centers. Secondary exploratory analyses showed that the degree of LAC deficiency reflected both the severity and age of onset of MDD. Moreover, these analyses showed that the decrease in LAC was larger in patients with a history of treatment-resistant depression (TRD), among whom childhood trauma and, specifically, a history of emotional neglect and being female, predicted the decreased LAC. These findings suggest that LAC may serve as a candidate biomarker to help diagnose a clinical endophenotype of MDD characterized by decreased LAC, greater severity, and earlier onset as well as a history of childhood trauma in patients with TRD. Together with studies in rodents, these translational findings support further exploration of LAC as a therapeutic target that may help to define individualized treatments in biologically based depression subtype consistent with the spirit of precision medicine.

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

Acetyl-l-carnitine deficiency in patients with major depressive disorder

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study

A Sensitive and Practical RP-HPLC-FLD for Determination of the Low Neuroactive Amino Acid Levels in Body Fluids and Its Application in Depression

Carnitine and Depression

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

Integrating Functional Neuroimaging and Serum Proteins Improves the Diagnosis of Major Depressive Disorder.

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder

Elevated SCN11A Concentrations Associated with Lower Serum Lipid Levels in Patients with Major Depressive Disorder

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Identification and Validation of Urinary Metabolite Biomarkers for Major Depressive Disorder

Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort

A novel urinary metabolite signature for diagnosing major depressive disorder.

Erythrocyte Membrane Fatty Acid Composition As a Potential Biomarker for Depression.

Combined Serum IL-6, C-reactive Protein, and Cortisol May Distinguish Patients with Anhedonia in Major Depressive Disorder.

Decreased Plasma Neuroactive Amino Acids and Increased Nitric Oxide Levels in Melancholic Major Depressive Disorder.

Unlocking the Potential of the 3-Hydroxykynurenine/kynurenic Acid Ratio: a Promising Biomarker in Adolescent Major Depressive Disorder